Anti-IL-27 antibodies and uses thereof
US11332524B2 · kind B2 · utility
1Cited by
37References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 22, 2019 |
| Grant date | May 17, 2022 |
| Priority date | — |
| Expiry date | Mar 22, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.